文献速递消化与肝胆胰病理细胞病理与分子病理

ALK阳性间叶性肿瘤的ALK易位:诊断与治疗见解

ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights.
PubMed 文献 · Arch Pathol Lab Med · 2022-01-01

该研究评估了7例ALK阳性间叶性肿瘤(排除炎性肌纤维母细胞瘤)的分子病理及对ALK靶向治疗的反应。ALK免疫标记所有患者阳性,6例可检测中5例发现ALK基因重排,3例检出融合伴侣;3例转移患者接受ALK抑制剂,1例部分缓解,2例疾病稳定。分子检测有助于准确诊断和个体化治疗。

要点

  • ALK免疫阳性间叶性肿瘤应行FISH或NGS检测ALK重排。
  • ALK融合伴侣包括PRKAR1A-ALK、TNS1-ALK和KIF5B-ALK。
  • ALK抑制剂在部分转移性ALK阳性间叶性肿瘤中有效。

核心结论

  • 对ALK阳性间叶性肿瘤进行分子检测可助准确诊断和个体化治疗。

研究设计与样本

  • 纳入7例ALK免疫异常表达的间叶性肿瘤患者,排除炎性肌纤维母细胞瘤,采用FISH或NGS检测ALK重排。

主要发现

  • ALK免疫标记所有患者阳性,6例弥漫(≥50%),1例部分(10%-50%)。
  • 6例可检测患者中5例发现ALK基因重排。
  • 4例检测融合伴侣的患者中3例检出:PRKAR1A-ALK、TNS1-ALK和KIF5B-ALK。
  • 1例ALK阳性炎性上皮样细胞肉瘤未检出ALK易位,但转录组显示ALK相关通路显著富集。
  • 3例转移患者接受ALK抑制剂:1例部分缓解,2例疾病稳定。

临床怎么用

  • 对ALK免疫阳性的间叶性肿瘤应考虑分子检测以明确诊断。
  • 检出ALK融合的患者可考虑ALK靶向治疗。

局限性

  • 样本量小(7例),部分检测未完成(融合伴侣仅4例检测)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: A wide spectrum of mesenchymal tumors harboring ALK gene rearrangements has been identified outside the archetypal example of ALK-positive inflammatory myofibroblastic tumors. OBJECTIVE.—: To evaluate the molecular pathology of unusual ALK-positive mesenchymal tumors and their response to ALK-targeted treatments. DESIGN.—: Seven patients with ALK-positive mesenchymal tumors, including inflammatory epithelioid cell sarcoma, undifferentiated sarcoma, histiocytic neoplasm, smooth muscle tumor of uncertain malignant potential (STUMP), and atypical fibrohistiocytic tumor, were included on the basis of aberrant ALK immunoexpression. Patients with inflammatory myofibroblastic tumors were excluded from the study. ALK gene rearrangement was investigated either by fluorescence in situ hybridization or next-generation sequencing. RESULTS.—: ALK was immunolabeled in all patients, diffusely (≥50%) in 6 patients and partially (10%-50%) in 1 patient. ALK gene rearrangement was discovered in 5 of the 6 available patients. The 3'-partners of ALK fusion were identified in 3 of 4 investigated patients as follows: PRKAR1A-ALK (ALK-positive histiocytic neoplasm), TNS1-ALK (STUMP), and KIF5B-ALK (ALK-positive atypical fibrohistiocytic tumor). We failed to discover ALK translocation in 1 patient with ALK-positive inflammatory epithelioid cell sarcoma. However, transcriptomic investigation showed that this tumor was significantly enriched with ALK-related pathways, which suggested activation of ALK through a nontranslocation pathway, as a constitutive oncogenic mark in this tumor. ALK-targeted inhibitors, which were administered to 3 patients with metastatic diseases, achieved partial remission in 1 patient with ALK-positive inflammatory epithelioid cell sarcoma and stable disease in patients with ALK-positive undifferentiated sarcoma and STUMP. CONCLUSIONS.—: Molecular investigation of ALK-positive mesenchymal neoplasms could allow for an accurate diagnosis and personalized treatment.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Jung M, Moon KC, Bae J, et al. ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights. Arch Pathol Lab Med. 2022. PMID: 35438749. doi:10.5858/arpa.2021-0330-OA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。